Phase II single arm study of durvalumab and olaparib (D plus O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)

被引：0
|
作者：
Fujii, T. [1 ]
Lipkowitz, S. [1 ]
Zimmer, A. D. S. [1 ]
Villanueva, E. [1 ]
Solarz, B. B. [1 ]
Lee, J-M. [1 ]
机构：
[1] Natl Canc Insitute, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.611
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435P
引用
收藏
页码：S364 / S364
页数：1
相关论文
共 50 条
  • [41] Phase II study of olaparib plus durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    Kaufman, B.
    Banerjee, S.
    Lortholary, A.
    Hong, S. H.
    Park, Y. H.
    Zimmermann, S.
    Roxburgh, P.
    Ferguson, M.
    Alvarez, R. H.
    Domchek, S.
    Gresty, C.
    Angell, H. K.
    Ros, V. Rocher
    Meyer, K.
    Lanasa, M.
    Herbolsheimer, P.
    de Jonge, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
    Gelmon, Karen
    Walker, Graham P.
    Fisher, Graham V.
    CANCER RESEARCH, 2018, 78 (04)
  • [43] A randomized, parallel-arm, phase H trial to assess the efficacy of preoperative ixahepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC).
    Rodriguez, Angel Augusto
    Salazar, Nina
    Patel, Tejal Amar
    Mejia, Jaime Alberto
    Froehlich, Amber
    Sneige, Nour
    Amin, Sapna
    Weiss, Heidi
    Rivera, Edgardo
    Chang, Jenny Chee Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
    Yaxin Liu
    Wei Wang
    Rutie Yin
    Youzhong Zhang
    Yu Zhang
    Keqiang Zhang
    Hongming Pan
    Ke Wang
    Ge Lou
    Guiling Li
    Ruyan Zhang
    Kun Li
    Jing Rao
    Ben Zhang
    Yuting Wang
    Quanren Wang
    Yunong Gao
    Huiping Li
    BMC Medicine, 21
  • [45] Phase II study of camrelizumab plus chemotherapy as neoadjuvant therapy in patients with early triple-negative breast cancer
    Wang, Y.
    Liu, Y.
    Zhu, S.
    Bi, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S616 - S616
  • [46] A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
    Liu, Yaxin
    Wang, Wei
    Yin, Rutie
    Zhang, Youzhong
    Zhang, Yu
    Zhang, Keqiang
    Pan, Hongming
    Wang, Ke
    Lou, Ge
    Li, Guiling
    Zhang, Ruyan
    Li, Kun
    Rao, Jing
    Zhang, Ben
    Wang, Yuting
    Wang, Quanren
    Gao, Yunong
    Li, Huiping
    BMC MEDICINE, 2023, 21 (01)
  • [47] Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial
    Liu, Jieqiong
    Tian, Zhenluan
    Wang, Ying
    Lin, Ying
    Li, Hengyu
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC)
    Matulonis, Ursula
    Wulf, Gerburg M.
    Birrer, Michael J.
    Westin, Shannon Neville
    Quy, Philippa
    Bell-McGuinn, Katherine M.
    Lasonde, Brian
    Whalen, Christin
    Aghajanian, Carol
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
    Buisseret, Laurence
    Loirat, Delphine
    Aftimos, Philippe
    Maurer, Christian
    Punie, Kevin
    Debien, Veronique
    Kristanto, Paulus
    Eiger, Daniel
    Goncalves, Anthony
    Ghiringhelli, Francois
    Taylor, Donatienne
    Clatot, Florent
    Van den Mooter, Tom
    Ferrero, Jean-Marc
    Bonnefoi, Herve
    Canon, Jean-Luc
    Duhoux, Francois P.
    Mansi, Laura
    Poncin, Renaud
    Barthelemy, Philippe
    Isambert, Nicolas
    Denis, Zoe
    Catteau, Xavier
    Salgado, Roberto
    Agostinetto, Elisa
    de Azambuja, Evandro
    Rothe, Francoise
    Craciun, Ligia
    Venet, David
    Romano, Emanuela
    Stagg, John
    Paesmans, Marianne
    Larsimont, Denis
    Sotiriou, Christos
    Ignatiadis, Michail
    Piccart-Gebhart, Martine
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [50] Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
    Laurence Buisseret
    Delphine Loirat
    Philippe Aftimos
    Christian Maurer
    Kevin Punie
    Véronique Debien
    Paulus Kristanto
    Daniel Eiger
    Anthony Goncalves
    François Ghiringhelli
    Donatienne Taylor
    Florent Clatot
    Tom Van den Mooter
    Jean-Marc Ferrero
    Hervé Bonnefoi
    Jean-Luc Canon
    Francois P. Duhoux
    Laura Mansi
    Renaud Poncin
    Philippe Barthélémy
    Nicolas Isambert
    Zoë Denis
    Xavier Catteau
    Roberto Salgado
    Elisa Agostinetto
    Evandro de Azambuja
    Françoise Rothé
    Ligia Craciun
    David Venet
    Emanuela Romano
    John Stagg
    Marianne Paesmans
    Denis Larsimont
    Christos Sotiriou
    Michail Ignatiadis
    Martine Piccart-Gebhart
    Nature Communications, 14
12345